CoChat

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Open access
Ha, Kyungsoo, Fiskus, Warren, Choi, Dong Soon, Bhaskara, Srividya, Cerchietti, Leandro, Devaraj, Santhana G. T., Shah, Bhavin, Sharma, Sunil, Chang, Jenny C., Melnick, Ari M., Hiebert, Scott, Bhalla, Kapil N. · 2014 · Oncotarget
Cited by 157

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

// Kyungsoo Ha 1 , Warren Fiskus 2,* , Dong Soon Choi 2,* , Srividya Bhaskara 3 , Leandro Cerchietti 4 , Santhana G. T. Devaraj 2 , Bhavin Shah 2 , Sunil Sharma 3 , Jenny C. Chang 2 , Ari M. Melnick 4 , Scott Hiebert 5 and Kapil N. Bhalla 2 1 Georgia Regents University, Augusta, GA 2 Houston Methodist Research Institute, Houston, TX 3 Huntsman Cancer Institute, Salt Lake City, UT 4 Weill Cornell Medical College, New York, NY 5 Vanderbilt University, Nashville, TN * These authors contributed equally to this work Correspondence: Kapil N. Bhalla, email: // Keywords : HDAC inhibitor, Triple Negative Breast Cancer, PARP inhibitor, BRCAness Received : May 13, 2014 Accepted : June 29, 2014 Published : June 30, 2014 Abstract There is an unmet need to develop new, more effective and safe therapies for the aggressive forms of triple negative breast cancers (TNBCs). While up to 20% of women under 50 years of age with TNBC harbor germline mutations in BRCA1, and these tumors are sensitive to treatment with poly(ADP) ribose polymerase inhibitors, a majority of TNBCs lack BRCA1 mutations or loss of expression. Findings presented here demonstrate that by attenuating the levels of DNA damage response and homologous recombination proteins, pan-histone deacetylase inhibitor (HDI) treatment induces ‘BRCAness’ and sensitizes TNBC cells lacking BRCA1 to lethal effects of PARP inhibitor or cisplatin. Treatment with HDI also induced hyperacetylation of nuclear hsp90. Similar effects were observed following shRNA-mediated depletion of HDAC3, confirming its role as the deacetylase for nuclear HSP90. Furthermore, cotreatment with HDI and ABT-888 induced significantly more DNA strand breaks than either agent alone, and synergistically induced apoptosis of TNBC cells. Notably, co-treatment with HDI and ABT-888 significantly reduced in vivo tumor growth and markedly improved the survival of mice bearing TNBC cell xenografts. These findings support the rationale to interrogate the clinical activity of this novel combination against human TNBC, irrespective of its expression of mutant BRCA1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2154

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 157

Metadata

Authors
Ha, K., Fiskus, W., Choi, D. S., Bhaskara, S., Cerchietti, L., Devaraj, S. G. T., Shah, B., Sharma, S., Chang, J. C., Melnick, A. M., Hiebert, S., & Bhalla, K. N.
Venue
Oncotarget
Published
2014-06-30
Volume
5
Issue
14
Pages
5637-5650
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2116735990
Cited by
157
References
10
FWCI
6.89
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.